Patent · US Active

Treatment of eosinophil or mast cell related disorders

US10774146B2 · kind B2 · utility

2Cited by

40References

7Claims

0Family size

Assignee

Celldex Therapeutics, Inc. · US

Inventors

Theresa LaVallee · Rockville, US
Gerald McMahon · San Francisco, US

Key dates

Filing date	Feb 7, 2019
Grant date	Sep 15, 2020
Priority date	—
Expiry date	Feb 7, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.